Heart failure in patients with congenital heart disease after a cancer diagnosis

被引:0
作者
Karazisi, Christina [1 ,2 ]
Dellborg, Mikael [1 ,2 ,3 ]
Mellgren, Karin [4 ]
Giang, Kok Wai [1 ,2 ]
Skoglund, Kristofer [1 ]
Eriksson, Peter [1 ,2 ,3 ]
Mandalenakis, Zacharias [1 ,2 ,3 ]
机构
[1] Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Mol & Clin Med, Diagnosvagen 11, SE-41650 Gothenburg, Sweden
[2] Sahlgrens Univ Hosp, Dept Med Geriatr & Emergency Med, Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Adult Congenital Heart Dis Unit, Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Queen Silvia Childrens Hosp, Dept Pediat Oncol, Gothenburg, Sweden
来源
ESC HEART FAILURE | 2024年 / 11卷 / 05期
基金
瑞典研究理事会;
关键词
cancer; cancer treatment; cardio-oncology; cardiotoxicity; congenital heart disease; heart failure; SURVIVORS; RISK;
D O I
10.1002/ehf2.14945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsIndividuals with congenital heart disease (CHD) are at an increased risk for cancer. As cancer survival rates improve, the prevalence of late side effects, such as heart failure (HF), is becoming more evident. This study aims to evaluate the risk of developing HF following a cancer diagnosis in patients with CHD, compared with those without CHD and with CHD patients who do not have cancer.MethodsCHD patients (n = 69 799) and randomly selected non-CHD controls (n = 650 406), born in Sweden between 1952 and 2017, were identified from the Swedish National Health Registers and Total Population Register (excluding those with syndromes and transplant recipients). CHD patients who developed cancer (n = 1309) were propensity score-matched with non-CHD patients who developed cancer (n = 9425), resulting in a cohort of 1232 CHD patients with cancer and 2602 non-CHD controls with cancer (after exclusion of individuals with HF prior to cancer diagnosis). In a separate analysis, CHD patients with cancer were propensity score-matched with CHD patients without cancer (n = 68 490). A total of 1233 CHD patients with cancer and 2257 CHD patients without cancer were included in the study.ResultsAmong CHD patients with cancer, 73 (5.9%) developed HF during a mean follow-up time of 8.5 +/- 8.7. Comparatively, in the propensity-matched control population, 29 (1.1%) non-CHD cancer patients (mean follow-up time of 7.3 +/- 7.5) and 101 (4.5%) CHD patients without cancer (mean follow-up time of 9.9 +/- 9.2) developed HF. CHD patients exhibited a significantly higher risk of HF post-cancer diagnosis compared with the non-CHD control group [hazard ratio (HR) 4.39, 95% confidence interval (CI) 2.83-6.81], after adjusting for age at cancer diagnosis and comorbidities. In the analysis between CHD patients with cancer and those without cancer, the results indicated a significantly higher risk of developing HF in CHD patients with cancer (HR 1.53, 95% CI 1.13-2.07).ConclusionsCHD patients face a more than four-fold increased risk of developing HF after a cancer diagnosis compared with cancer patients without CHD. Among CHD patients, the risk of HF is only modestly higher for those with cancer than for those without cancer. This suggests that the increased HF risk in CHD patients with cancer, relative to non-CHD cancer patients, may be more attributable to CHD itself than to cancer treatment-related side effects.
引用
收藏
页码:2481 / +
页数:977
相关论文
共 18 条
  • [11] The Risk of Cancer in Patients with Congenital Heart Disease: A Nationwide Population-Based Cohort Study in Taiwan
    Lee, Yu-Sheng
    Chen, Yung-Tai
    Jeng, Mei-Jy
    Tsao, Pei-Chen
    Yen, Hsiu-Ju
    Lee, Pi-Chang
    Li, Szu-Yuan
    Liu, Chia-Jen
    Chen, Tzeng-Ji
    Chou, Pesus
    Soong, Wen-Jue
    [J]. PLOS ONE, 2015, 10 (02):
  • [12] Refining the 10-Year Prediction of Left Ventricular Systolic Dysfunction in Long-Term Survivors of Childhood Cancer
    Leerink, Jan M.
    van der Pal, Helena J. H.
    Kremer, Leontien C. M.
    Feijen, Elizabeth A. M.
    Meregalli, Paola G.
    Pourier, Milanthy S.
    Merkx, Remy
    Bellersen, Louise
    van Dalen, Elvira C.
    Loonen, Jacqueline
    Pinto, Yigal M.
    Kapusta, Livia
    Mavinkurve-Groothuis, Annelies M. C.
    Kok, Wouter E. M.
    [J]. JACC: CARDIOONCOLOGY, 2021, 3 (01): : 62 - 72
  • [13] Lyon Alexander R, 2022, Eur Heart J Cardiovasc Imaging, V23, pe333, DOI [10.1093/eurheartj/ehac244, 10.1093/ehjci/jeac106]
  • [14] Survival in Children With Congenital Heart Disease: Have We Reached a Peak at 97%?
    Mandalenakis, Zacharias
    Giang, Kok Wai
    Eriksson, Peter
    Liden, Hans
    Synnergren, Mats
    Wahlander, Hakan
    Fedchenko, Maria
    Rosengren, Annika
    Dellborg, Mikael
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (22):
  • [15] Risk of Cancer Among Children and Young Adults With Congenital Heart Disease Compared With Healthy Controls
    Mandalenakis, Zacharias
    Karazisi, Christina
    Skoglund, Kristofer
    Rosengren, Annika
    Lappas, Georgios
    Eriksson, Peter
    Dellborg, Mikael
    [J]. JAMA NETWORK OPEN, 2019, 2 (07)
  • [16] Petersen C, 2023, Lakartidningen, V120, P22141
  • [17] R Core Team, 2022, R LANG ENV STAT COMP
  • [18] Regionala cancercentrum i samverkan, 2022, LNGTIDSUPPFLJNING EF